Arcus Biosciences reported a total revenue of $28 million for the first quarter of 2025, a significant decrease from $145 million in the same period of 2024. The company recorded a net loss of $112 million, compared to a net loss of $4 million in Q1 2024. Despite the financial results, Arcus maintained a strong cash position with $1.0 billion in cash, cash equivalents, and marketable securities.
Total revenues for Q1 2025 were $28 million, down from $145 million in Q1 2024.
Net loss for Q1 2025 was $112 million, compared to $4 million in Q1 2024.
Research and Development (R&D) expenses increased to $122 million in Q1 2025 from $109 million in Q1 2024.
Cash, cash equivalents, and marketable securities stood at $1.0 billion as of March 31, 2025.
Arcus Biosciences expects to recognize GAAP revenue of between $75 million and $90 million for the full year 2025. The company believes its current cash, cash equivalents, and marketable securities, along with available facilities, will be sufficient to fund operations through initial pivotal readouts for domvanalimab, quemliclustat, and casdatifan, including PEAK-1.
Analyze how earnings announcements historically affect stock price performance